
California's Scary Warning Labels Might Be Working, Study Says
The warnings, on thousands of products sold in California, are stark.
'Use of the following products,' one label says, 'will expose you to chemicals known to the State of California to cause cancer, birth defects or other reproductive harm.'
Now, new research shows the warnings may be working.
A study published Wednesday in the journal Environmental Science & Technology found that California's right-to-know law, which requires companies to warn people about harmful chemicals in their products, has swayed many companies to stop using those chemicals altogether.
As it turns out, companies don't want to sell a product that carries a big cancer warning label, said Dr. Megan Schwarzman, a physician and environmental-health scientist at the University of California, Berkeley School of Public Health and an author of the study. Combine that with the threat of lawsuits and reputational costs, as well as companies just wanting to do the right thing for health, and 'it becomes a great motivator for change,' she said.
California maintains a list of about 900 chemicals known to cause cancer and other health effects. Under the 1986 right-to-know law, also known as Prop 65, products that could expose people to harmful amounts of those chemicals must carry warning labels.
Critics had long mocked the measure, saying the warnings were so ubiquitous — affixed to cookware, faux leather jackets, even baked goods — that they had become largely meaningless in the eyes of shoppers. But the latest study found that companies, more than consumers, may be most influenced by the warnings.
To assess the law's effect, researchers carried out interviews at 32 global manufacturers and retailers that sell clothing, personal-care, cleaning, and a range of home products. Almost 80 percent of interviewees said Prop 65 had prompted them to reformulate their products.
Companies can avoid the warning labels if they reduce the level of any Prop 65 chemicals below a 'safe harbor' threshold.
A similar share of companies said they looked to Prop 65 to determine which chemicals to avoid. And 63 percent said the law had prompted them to also reformulate products they sold outside California.
The American Chemistry Council, which represents chemical manufacturers, did not immediately respond to a request for comment on the study.
No other state has a law quite like Prop. 65, requiring warnings on such a wide range of products about cancer or reproductive harm. New York enacted a more limited law in 2020 that requires manufacturers to disclose certain chemicals in children's products and that bans the use of certain chemicals by 2023. Other states have laws geared toward disclosure of ingredients on labels.
California, meanwhile, is pushing ahead. A 2018 change to Prop 65 has meant products are starting to carry even more specific labels. Some food and beverage cans, for example, may carry labels that warn that they 'have linings containing bisphenol A (BPA), a chemical known to the State of California to cause harm to the female reproductive system.'
The latest research is part of a larger effort to analyze Prop 65's effect on people's exposure to toxic chemicals. In a study published last year, researchers at the Silent Spring Institute and UC Berkeley found that in the years after certain chemicals were listed under the law, levels of those chemicals in people's bodies decreased both in California and nationwide.
That research came with a caveat, however. In some examples where levels of a listed chemical decreased, a close substitute to that chemical, potentially with similar harmful effects, increased. Prop 65 has no mechanism to check the safety of alternative chemicals.
It suggested that stronger policies were needed at both the federal and state levels to study and regulate the thousands of chemicals on the market, Dr. Schwarzman said. 'This is so much bigger than the individual consumer and what we choose off-the-shelf,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
an hour ago
- Bloomberg
Norway Takes Drone Inspections of Offshore Oil Platform to a New Level
A major Norwegian oil field is taking the industry's use of drones for safety inspections to a new level, with a permanently installed aircraft that's operated remotely from the shore. From a control room in Norway's oil capital of Stavanger, pilots are performing drone inspections of the Edvard Grieg platform some 180 kilometers out at sea. The technology is a step toward fully autonomous inspections, requiring fewer workers to be sent offshore, according to its operator Aker Solutions ASA.


New York Post
11 hours ago
- New York Post
Microplastics in your food are contributing to these two health issues: study
You know microplastics are showing up in your take out containers and your junk food. But alarming fresh research indicates they're present in pretty much anything you consume — and the effects of these tiny particles are from far teeny. 3 New research raises red flags about what all that invisible plastic might be doing to the human body. molenira – Advertisement A new study in mice suggests that microplastics found in food and drink could be interfering with blood sugar levels and damaging the liver. Researchers at the University of California, Davis, found that animals who consumed polystyrene nanoplastics — the kind of plastic used in food packaging — developed glucose intolerance and signs of liver injury, two serious health issues that may have long-term consequences. Advertisement The findings — which were presented at the annual meeting of the American Society for Nutrition on Sunday — raise red flags about what all that invisible plastic might be doing to the human body. 'With the growing concern around micro- and nanoplastic exposure, we wanted to evaluate the impact of this exposure on health,' lead author Amy Parkhurst, a doctoral candidate at UC Davis, said in a press release. Parkhurst and her team fed mice a standard diet spiked with a daily dose of polystyrene nanoparticles, mimicking the way people are exposed through food and drinks. 3 The study suggests that microplastics found in food and drink could be interfering with blood sugar levels and damaging the liver. – Advertisement The dose was chosen to reflect real-world human exposures — which could range from tens of thousands to millions of particles per year, according to previous estimates. Compared to their plastic-free peers, the mice that ate nanoplastics had trouble regulating blood sugar — a condition known as glucose intolerance, which can be a warning sign for diabetes. The plastic-dosed mice also had higher levels of a liver enzyme called ALT — a common marker for liver injury. 3 On top of that, the study found that the plastics made the gut more 'leaky,' allowing harmful substances to enter the bloodstream and potentially stress the liver even more. Crystal light – Advertisement On top of that, the study found that the plastics made the gut more 'leaky,' allowing harmful substances to enter the bloodstream and potentially stress the liver even more. While the findings come from mice, not humans, they add to a growing pile of research raising questions about how microplastics — which are now found everywhere from bottled water to seafood — might be affecting our health. 'We can't control for all the plastics the mice are exposed to,' Parkhurst noted, 'However, our study design allowed us to see dose-correlated changes since the nanoplastics-dosed group would have a higher exposure.' Parkhurst emphasized that more research is needed to understand how these particles affect people and whether they pose similar risks in the long term. Still, the message is clear: what's too small to see might not be too small to hurt.
Yahoo
12 hours ago
- Yahoo
Cathie Wood buys $13.9 million of popular AI stock
Cathie Wood buys $13.9 million of popular AI stock originally appeared on TheStreet. Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when prices dip. This is what she did in late May, adding shares of a popular AI company after a pullback. 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰💵 Wood's funds saw a brief bump after Trump won the presidency last November, but that momentum didn't go far. Her flagship Ark Innovation ETF () underperformed the S&P 500 index amid broader market volatility this year. Year-to-date, ARKK is down 2.15%, while the S&P 500 index is up 0.51%. Wood gained a remarkable 153% in 2020, which helped build her reputation and attract loyal investors. Still, her long-term performance has made many others skeptical of her aggressive style. As of May 30, Ark Innovation ETF, with $5 billion under management, has delivered a five-year annualized return of negative 1.66%. In comparison, the S&P 500 has an annualized return of 15.94% over the same period. Wood's investment strategy is straightforward: Her Ark ETFs typically buy shares in emerging high-tech companies in fields such as artificial intelligence, blockchain, biomedical technology, and robotics. Wood says these companies have the potential to reshape industries, but their volatility leads to major fluctuations in Ark funds' Ark Innovation ETF wiped out $7 billion in investor wealth over the 10 years ending in 2024, according to an analysis by Morningstar's analyst Amy Arnott. That made it the third-biggest wealth destroyer among mutual funds and ETFs in Arnott's ranking. Wood recently said the U.S. is coming out of a three-year 'rolling recession' and heading into a productivity-led recovery that could trigger a broader bull market. In a letter to investors published last month, she dismissed recession predictions as she expects "more clarity on tariffs, taxes, regulations, and interest rates over the next three to six months." "If the current tariff turmoil results in freer trade, as tariffs and non-tariff barriers come down in tandem with declines in other taxes, regulations, and interest rates, then real GDP growth and productivity should surprise on the high side of expectations at some point during the second half of this year," she wrote. She also struck an optimistic tone for tech stocks. "During the current turbulent transition in the U.S., we think consumers and businesses are likely to accelerate the shift to technologically enabled innovation platforms including artificial intelligence, robotics, energy storage, blockchain technology, and multiomics sequencing," she said. But not everyone shares Wood's bullish outlook. Her flagship Ark Innovation ETF has seen $2.02 billion in net outflows over the past year through May 29, including nearly $144 million in the last month alone, according to ETF research firm VettaFi. On May 28, Wood's Ark funds bought 251,080 shares of Tempus AI () . That chunk of stock was valued at roughly $13.9 million as of May 30's close. Wood has been actively buying Tempus AI's stock since last June's IPO. Former Speaker of the House Nancy Pelosi also bets on this stock. In January, Pelosi bought 50 call options (a bet that a stock will rise) for Tempus AI valued at least $50, AI is a health technology company founded in 2015. It uses AI for diagnostics and helps physicians make personalized, data-driven decisions. The stock plunged more than 19% on May 28 after short-seller Spruce Point Capital Management released a report raising concerns about management's alleged history of promoting disruptive technology companies with revenue recognition issues and shareholder losses. The report also questioned the validity of Tempus AI's artificial intelligence services, citing minimal revenues and product demonstrations. Tempus AI responded that the report is "riddled with hypotheticals and inaccuracies and fails to address Tempus' history of strong financial performance and impressive growth." Wood's team said it has investigated the credibility of these allegations. The team believes that Tempus AI "remains focused on delivering data-driven, AI-enabled, patient-centered diagnostics and improving outcomes through precision medicine," according to a weekly letter to investors. Despite that tumble, Tempus AI stock has surged 63% year-to-date. On May 6, the company reported first-quarter results, with revenue climbing 75.4% year-over-year to $255.7 million. Gross profit surged 99.8% to $155.2 million, driven by continued margin gains in its Genomics and Data and Services segments. It raised its full-year 2025 revenue forecast to $1.25 billion, reflecting roughly 80% growth from the previous year. However, the company is still not profitable, and net loss for the quarter widened to $68 million from $64.7 million. Wood says health care is the "most underappreciated application of AI." 'We've got 37 trillion cells in our body, and they're going to be sequenced as we're looking for cures,' Wood told CNBC in February. 'I think the most underappreciated application of AI is health care. I think health care is responsible for an incredible amount of storage out there right now. Data is the name of the game.' Fund manager buys and sells See a big stock rally ahead? Be patient, money manager says Fund manager, skeptical of AI, backs shocking stock Veteran fund manager sends surprising message on the weak dollar As of May 31, Tempus AI ranked sixth among Ark Innovation ETF's holdings, accounting for 5.1% of the portfolio with a market value of $284.8 million. Wood's latest trades this week also include buying shares of Nvidia () , Advanced Micro Devices () , Iridium Communications () , Intuitive Machines () , and Intellia Therapeutics () . At the same time, she trimmed positions in Tesla () , Roblox () , and CoreWeave () .Cathie Wood buys $13.9 million of popular AI stock first appeared on TheStreet on Jun 1, 2025 This story was originally reported by TheStreet on Jun 1, 2025, where it first appeared. Sign in to access your portfolio